Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290849 | 0.76 | KDM4E (1.00) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL29432549 | 0.76 | KDM4E (1.00) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL30987223 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| Hydrochloric Acid SCHEMBL28576259 | 0.74 | KDM4E (0.95) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| Hydrochloric Acid SCHEMBL28576260 | 0.74 | KDM4E (0.95) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL446289 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL4204967 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL3810651 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL12329 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11829036-B2 | Optically anisotropic multilayer product and method for producing same | ZEON CORPORATION (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4225315-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | Nimmune Biopharma, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4196475-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | SHIONOGI & CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1939175-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi&Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1932839-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1916245-A1 | INDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1911759-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-0678505-B1 | Oximethers and fungicides containing them | BASF AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| EP-0679636-A1 | Oximethers and fungicides containing them | BASF Aktiengesellschaft (DE) | 1995-11-02 | — | — | EP | disclosed |
| EP-0678505-A1 | Oximethers and fungicides containing them | BASF AKTIENGESELLSCHAFT (DE) | 1995-10-25 | — | — | EP | disclosed |
| US-5446067-A | For treatment of crops, seeds, soils | BASF AKTIENGESELLSCHAFT (DE) | 1995-08-29 | — | — | US | disclosed |
| EP-0498188-A2 | Oximethers and fungicides containing them | BASF Aktiengesellschaft (DE) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | MAPT 1949/4885KDM4E 3554/4885ALDH1A1 4156/4885 |
| US-20230192652-A1 | PLXDC2 LIGANDS | PLP2, PDCD1LG2, LCP2 | MAPT 300/4885KDM4E 3914/4885ALDH1A1 3872/4885 |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | HRH2, PTGDR, CNR2 | MAPT 4656/4885KDM4E 2680/4885ALDH1A1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.